India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Marksans Pharma posted its highest-ever quarterly EBITDA (INR 213 crore) and PAT (INR 159 crore) in Q1FY27, with UK and Europe overtaking as a genuine second growth engine.</li>
<li>Operating leverage, a bolt-on European buildout and a cash pile crossing INR 1,000 crore reshape the growth and capital allocation narrative heading into FY27.</li>
<li>Management's conservative guidance hold, flagged margin normalization and looming capacity constraints deserve closer scrutiny than the headline beat suggests.</li>
</ul>


Marksans Pharma posted its highest-ever quarterly EBITDA (INR 213 crore) and PAT (INR 159 crore) in Q1FY27, with UK and Europe overtaking as a genuine second growth engine.
Operating leverage, a bolt-on European buildout and a cash pile crossing INR 1,000 crore reshape the growth and capital allocation narrative heading into FY27.
Management's conservative guidance hold, flagged margin normalization and looming capacity constraints deserve closer scrutiny than the headline beat suggests.


Marksans Pharma: Europe- The Next Growth Engine!

External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Targeted M&amp;A and Strategic Expansion in European Regulated Markets: Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and Germany-based GmbH, alongside establishing operating entities in Ireland and Germany.</li><li>The transactions broaden the company's product portfolio beyond traditional store-brand over-the-counter (OTC) drugs to include high-margin prescription (Rx) formulations across regulated European markets.</li><li>Backed by a net cash balance of Rs 1,058 Cr, management is targeting Rs 1,000 Cr in European revenues over the next 3–5 years. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Targeted M&amp;A and Strategic Expansion in European Regulated Markets: Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and Germany-based GmbH, alongside establishing operating entities in Ireland and Germany.The transactions broaden the company's product portfolio beyond traditional store-brand over-the-counter (OTC) drugs to include high-margin prescription (Rx) formulations across regulated European markets.Backed by a net cash balance of Rs 1,058 Cr, management is targeting Rs 1,000 Cr in European revenues over the next 3–5 years. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Axis Punch: Marksans Pharma Ltd - 31st August, 2026

<ul>
<li>Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a 'Zero 483 Observation' clearance from the USFDA, completely de-risking its largest-ever capex.</li>
<li>This facility is the engine for the company's next growth phase. It will service a confirmed $220 million US order book and is critical to achieve INR 3,000 crore revenue.</li>
<li>With the capex phase now complete and de-risked, the focus shifts to execution and the strategic deployment of its INR 711 crore cash pile, likely on a European front-end acquisition.</li>
</ul>


Marksans Pharma's new, capacity-doubling Goa facility (acquired from Teva) just received a 'Zero 483 Observation' clearance from the USFDA, completely de-risking its largest-ever capex.
This facility is the engine for the company's next growth phase. It will service a confirmed $220 million US order book and is critical to achieve INR 3,000 crore revenue.
With the capex phase now complete and de-risked, the focus shifts to execution and the strategic deployment of its INR 711 crore cash pile, likely on a European front-end acquisition.


The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Sino Biopharmaceutical entered outlicensing deal with AstraZeneca for respiratory drug candidate TQC3721. Hansoh Pharmaceutical’s ADC drug candidate HS-20093 met primary endpoint of overall survival in Phase 3 trial for SCLC.</li>
<li>Wuxi Biologics’ Hebei drug substance manufacturing facility passed the Pre-License Inspection by the FDA. Astellas Pharma’s Padcev Keytruda combo was accepted for China review in perioperative muscle-invasive bladder cancer.</li>
<li>Otsuka’s Astex Pharmaceuticals inked R&amp;D deal with Genentech to identify small molecule breast cancer drug candidates. Celltrion’s Avastin biosimilar has secured formulary listings with two major PBMs in the U.S.</li>
</ul>


Sino Biopharmaceutical entered outlicensing deal with AstraZeneca for respiratory drug candidate TQC3721. Hansoh Pharmaceutical’s ADC drug candidate HS-20093 met primary endpoint of overall survival in Phase 3 trial for SCLC.
Wuxi Biologics’ Hebei drug substance manufacturing facility passed the Pre-License Inspection by the FDA. Astellas Pharma’s Padcev Keytruda combo was accepted for China review in perioperative muscle-invasive bladder cancer.
Otsuka’s Astex Pharmaceuticals inked R&amp;D deal with Genentech to identify small molecule breast cancer drug candidates. Celltrion’s Avastin biosimilar has secured formulary listings with two major PBMs in the U.S.


APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion

<ul>
<li>Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.</li>
<li>Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  </li>
<li>Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.</li>
</ul>


Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.
Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  
Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.


APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

India

Marksans Pharma Limited manufactures active ingredients that are used to produce finished drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Marksans Pharma (MRKS IN)

Marksans Pharma: Europe- The Next Growth Engine!

Marksans Pharma is evolving into a global OTC healthcare player, with Europe expansion, product launches and regional growth supporting a 15–20%...

Sudarshan Bhandari

Axis Punch: Marksans Pharma Ltd - 31st August, 2026

Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and...

Axis Direct

The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential

Marksans Pharma's new Goa facility, acquired from Teva, cleared by USFDA, de-risking capex for growth phase, focusing on execution and strategic...

Sudarshan Bhandari

APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion

Sino Bio stuck outlicensing deal with AstraZeneca. Hansoh’s ADC drug candidate met primary endpoint in Phase 3 trial. China will review Astellas’...

Tina Banerjee

APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

Celltrion inlicensed two antibody drug candidates in KRW1T deal. Dong-A got domestic approval for Xcopri. Hanmi Pharm will distribute Boehringer...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Marksans Pharma: Europe- The Next Growth Engine!

Marksans Pharma is evolving into a global OTC healthcare player, with Europe expansion, product launches and regional growth supporting a 15–20%...

Sudarshan Bhandari

Axis Punch: Marksans Pharma Ltd - 31st August, 2026

Marksans Pharma has strengthened its long-term growth strategy through front-end European acquisitions, including Netherlands-based QliniQ B.V. and...

Axis Direct

The Beat Ideas: Marksans Pharma - USFDA's 'Zero Observation' Unlocks ₹3,000 Crore Goa Potential

​Marksans Pharma's new Goa facility, acquired from Teva, cleared by USFDA, de-risking capex for growth phase, focusing on execution and strategic...

Sudarshan Bhandari

APAC Healthcare Weekly (July 12) – Sino Bio, Hansoh Pharma, Wuxi Bio, Astellas, Otsuka, Celltrion

Sino Bio stuck outlicensing deal with AstraZeneca. Hansoh’s ADC drug candidate met primary endpoint in Phase 3 trial. China will review Astellas’...

Tina Banerjee

APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

Celltrion inlicensed two antibody drug candidates in KRW1T deal. Dong-A got domestic approval for Xcopri. Hanmi Pharm will distribute Boehringer...

Tina Banerjee

Marksans Pharma's new Goa facility, acquired from Teva, cleared by USFDA, de-risking capex for growth phase, focusing on execution and strategic...